Merck fertility treatment corifollitropin alfa under FDA review
This article was originally published in Scrip
Executive Summary
The US FDA has accepted Merck's new drug application (NDA) for a standard 12-month review for the pharma's experimental fertility treatment corifollitropin alfa for controlled ovarian stimulation (COS) in women participating in assisted reproductive technology.